ACS Medicinal Chemistry Letters - The Consciousness Library

Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms

ACS Medicinal Chemistry Letters July 10, 2026 Anna C. Renner, Robert B. Kargbo

High Resolution Image Download MS PowerPoint Slide The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds,...

DOI: 10.1021/acsmedchemlett.6c00364 Aerosol Precision medicine Nanotechnology

Novel 6,5-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches

ACS Medicinal Chemistry Letters July 3, 2026 Ram W. Sabnis, Anika R. Sabnis

High Resolution Image Download MS PowerPoint Slide Provided herein are novel 6,5-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse, and headaches, and processes for preparing such compounds.

DOI: 10.1021/acsmedchemlett.6c00354 Headaches Receptor Agonist Drug discovery +1

Novel 5,6-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches

ACS Medicinal Chemistry Letters June 3, 2026 Ram W. Sabnis, Anika R. Sabnis

Provided herein are novel 5,6-bicyclic compounds as 5-HT2A receptor agonists, pharmaceutical compositions, use of such compounds in treating depression, anxiety, substance abuse and headaches, and processes for preparing such compounds.

DOI: 10.1021/acsmedchemlett.6c00270 Full text Headaches Agonist Receptor Drug +2

Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine–DMT Formulations

ACS Medicinal Chemistry Letters December 16, 2025 Anna C. Renner, Robert B. Kargbo

Emerging psychedelic therapeutics increasingly rely on mechanistic precision, receptor selectivity, and pharmacokinetic control. Recent inventions introduce simplified iboga analogs with tunable polypharmacology, real-time EEG biomarkers that individualize psilocybin dosing, and standardized harmine-DMT ratios with high bioavailability. Together, these innovations form a coherent framework for...

DOI: 10.1021/acsmedchemlett.5c00714 Full text Psilocybin Electroencephalography Hallucinogen Investigational drugs +1

Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric Therapeutics

ACS Medicinal Chemistry Letters December 16, 2025 Anna C. Renner, Robert B. Kargbo

New inventions introduce complementary advances across neuropsychiatric therapeutics: a blood-based gene-expression diagnostic centered on FOXG1 for objective PTSD detection; benzocyclobutenyl-methylamine modulators that normalize neuronal hyperexcitability; and templated-carrier sublingual 5-MeO-DMT formulations enabling controlled, nonhallucinogenic neuroplasticity. Together, these approaches...

DOI: 10.1021/acsmedchemlett.5c00716 Full text Scalability Computational biology Precision medicine Bioinformatics

Novel Psilocin Derivatives as Serotonergic Psychedelic Agents for Treating CNS Disorders

ACS Medicinal Chemistry Letters October 22, 2025 Ram W. Sabnis

High Resolution Image Download MS PowerPoint Slide Provided herein are novel psilocin derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating central nervous system (CNS) disorders, and processes for preparing such compounds.

DOI: 10.1021/acsmedchemlett.5c00608 Serotonergic Serotonin Central nervous system Hallucinogen +1

Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy

ACS Medicinal Chemistry Letters October 10, 2025 Anna C. Renner, Robert B. Kargbo

A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypical antipsychotics modulate serotonergic signaling to mitigate 5-HT2B-linked safety concerns. Together, these inventions advance formulation, mechanistic selectivity, and translational biomarkersoffering a chemistry-enabled path to scalable...

DOI: 10.1021/acsmedchemlett.5c00595

Novel Serotonergic Psychedelic Agents as 5-HT2A Agonists for Treating Psychosis, Mental Illness, and CNS Disorders

ACS Medicinal Chemistry Letters August 25, 2025 Ram W. Sabnis

High Resolution Image Download MS PowerPoint Slide Provided herein are novel serotonergic psychedelic agents as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.

DOI: 10.1021/acsmedchemlett.5c00484 Serotonergic Serotonin Psychosis Mental illness +3

Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome

ACS Medicinal Chemistry Letters August 15, 2025 Robert B. Kargbo

Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as...

DOI: 10.1021/acsmedchemlett.5c00475 Full text Psilocybin Agonism Hallucinogen Divergence linguistics +3

Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.

ACS Medicinal Chemistry Letters June 12, 2025 Ram W. Sabnis 4 citations

Provided herein are novel indole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.

DOI: 10.1021/acsmedchemlett.5c00309 Full text Brain conditions Neurological Psychiatric Psychosis +6

Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.

ACS Medicinal Chemistry Letters June 12, 2025 Robert B. Kargbo 1 citation

Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric...

DOI: 10.1021/acsmedchemlett.5c00265 Full text 5-MEO-DMT Treatment-resistant depression Entheogenic treatment Hallucinogen-assisted therapy +9

Design and Evaluation of Substituted Tryptamines for Nonpsychedelic Modulation of Metabolic and Neuropsychiatric Pathways.

ACS Medicinal Chemistry Letters June 12, 2025 Robert B. Kargbo

Substituted tryptamines with selective 5-HT2A/2C activity demonstrate therapeutic promise without psychedelic effects. Two recent patent applications describe nonhallucinogenic analogs for metabolic and neuropsychiatric disorders. These agents exhibit optimized receptor selectivity, metabolic synergy, and neuroplastic potential, offering a novel chemical framework for multimodal treatment...

DOI: 10.1021/acsmedchemlett.5c00263 Full text Drug development Drug discovery Pharmaceutical research Novel compounds +8

Reducing Cardiovascular Side Effects of DMT Using Beta-Blockers.

ACS Medicinal Chemistry Letters May 8, 2025 Robert B. Kargbo 1 citation

DMT induces rapid antidepressant effects, but acute sympathomimetic side effects, particularly hypertension and tachycardia, limit its use. This study describes coformulations with short-acting beta-blockers or nitrates, matched to DMT's pharmacokinetics, to mitigate peripheral cardiovascular risks without compromising central therapeutic action, facilitating safer psychedelic therapy in...

DOI: 10.1021/acsmedchemlett.5c00180 Full text Psychedelic therapy Cardiovascular medicine Mental health treatment Drug safety +1

Integrated Advancements in Neuroplasticity, Psychedelic Therapeutics, and AI-Driven Innovations for Precision Medicine.

ACS Medicinal Chemistry Letters April 10, 2025 Robert B. Kargbo

Recent advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms mark a new frontier in precision medicine. These innovations address critical challenges in neurological and psychiatric disorders, chronic pain management, and computational accessibility. By harnessing the principles of receptor modulation, targeted...

DOI: 10.1021/acsmedchemlett.5c00112 Full text

Unveiling Reality: Psychedelics, Neural Filtering, and the Future of Psychiatric Medicine.

ACS Medicinal Chemistry Letters April 10, 2025 Robert B. Kargbo

Psychedelics and AI modulate cognitive frameworks, disrupt rigid thought patterns, and enhance neuroplasticity, offering therapeutic potential for depression, PTSD, and addiction. Relaxing neural filters reveal altered states of consciousness, challenging perceptions of reality. This Viewpoint explores their neurobiological mechanisms and AI's role in augmenting psychiatric treatments.

DOI: 10.1021/acsmedchemlett.5c00103 Full text Brain plasticity Psychedelics Mental health Therapeutic technology

Targeting Phantom Pain with Psilocybin: Toward Integration with Adaptive Sensory Technologies

ACS Medicinal Chemistry Letters April 10, 2025 Robert B. Kargbo

Psilocybin demonstrates a clinically meaningful reduction in phantom and residual limb pain. Adaptive sensory environments (ASEs) separately offer biosensor-guided modulation of psychological states during psychoactive therapy. This Patent Highlight explores the pharmacological findings of a psilocybin trial and discusses future integration with ASE systems to precision and scale...

DOI: 10.1021/acsmedchemlett.5c00182 Psilocybin Sensory system Phantom limb Imaging phantom

Psychiatric Treatments with Short-Duration Psychedelics and AI-Driven Behavioral Monitoring.

ACS Medicinal Chemistry Letters February 13, 2025 Robert B. Kargbo

Integrating advanced pharmaceutical innovations and artificial intelligence (AI) offers transformative potential for psychiatric care. This Patent Highlight reviews novel therapeutic strategies, including the synergistic use of monoamine antidepressants and short-duration psychedelics, alongside AI-driven behavioral efficacy tracking. The combination of selective serotonin reuptake inhibitors...

DOI: 10.1021/acsmedchemlett.5c00031 Full text

Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.

ACS Medicinal Chemistry Letters January 9, 2025 Ram W. Sabnis 7 citations

Provided herein are novel 3-pyrrolidineindole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis and mental illnesses such as depression and post-traumatic stress disorder, and processes for preparing such compounds.

DOI: 10.1021/acsmedchemlett.4c00581 Full text

Harnessing Artificial Intelligence to Overcome Key Challenges in Psychedelic Research and Therapy.

ACS Medicinal Chemistry Letters January 9, 2025 Robert B. Kargbo

Artificial intelligence (AI) offers transformative potential in psychedelic research by addressing limitations in personalized treatment, predicting therapeutic outcomes, and understanding complex biological and environmental factors. AI-driven models provide new insights into long-term efficacy, set and setting optimization, and alternative treatment methods, advancing psychedelic therapy into...

DOI: 10.1021/acsmedchemlett.4c00548 Full text

Advanced Delivery Systems and Novel Psilocin Derivatives for Enhanced Therapeutic Applications.

ACS Medicinal Chemistry Letters December 12, 2024 Robert B. Kargbo

Psychedelic compounds, particularly psilocybin and psilocin, have shown significant therapeutic potential in treating neurological and psychiatric disorders. However, their bioavailability, rapid metabolism, and stability challenges have limited their clinical use. This Patent Highlight reviews recent innovations in psychedelic drug delivery systems and the development of psilocin analogs aimed...

DOI: 10.1021/acsmedchemlett.4c00521 Full text Psychedelics Mental health treatment Pharmaceutical research Drug development

Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment.

ACS Medicinal Chemistry Letters November 14, 2024 Robert B. Kargbo 3 citations

Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in treating various mental health disorders. This Patent Highlight evaluates findings from multiple recent patents that explore novel applications of these compounds, including their use in severe psychiatric conditions such as depression, anxiety, and...

DOI: 10.1021/acsmedchemlett.4c00490 Full text Psychedelic therapy Alternative medicine Depression treatment Therapeutic compounds +1

Expanding the Therapeutic Horizons of Psilocybin in Mental Health

ACS Medicinal Chemistry Letters October 15, 2024 Robert B. Kargbo 1 citation

Psilocybin, a naturally occurring psychedelic compound, has recently emerged as a promising therapeutic agent for mental health. This Patent Highlight explores the innovative approaches to harnessing psilocybin's potential across various contexts. These include clinical trials targeting severe psychiatric conditions, the integration of low-dose psilocybin into dietary products to promote...

DOI: 10.1021/acsmedchemlett.4c00488 Psilocybin New horizons Hallucinogen Mental health +1

Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine

ACS Medicinal Chemistry Letters August 21, 2024 Robert B. Kargbo

This article explores groundbreaking advancements in psychedelic research, highlighting the development of novel lysergic acid derivatives with modified LSD-like actions and innovative dosing methods based on ABCF1 gene expression for psilocybin. It also examines new strategies for treating binge eating disorder using psychedelics and techniques for neuroenhancement to enhance emotional...

DOI: 10.1021/acsmedchemlett.4c00414 Psilocybin Lysergic acid diethylamide Transformative learning Hallucinogen +1

Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience

ACS Medicinal Chemistry Letters August 21, 2024 Robert B. Kargbo

Recent advancements in medical research have focused on the utilization of entheogens, particularly psilocybin and its related compounds, as therapeutic agents in mitigating cognitive decline and enhancing psychological resilience in patients undergoing anesthesia and sedation. This Patent Highlight integrates findings from three patent applications, each contributing unique insights into the...

DOI: 10.1021/acsmedchemlett.4c00412 Surgical-medicine Mental-health Cognitive-function Psychedelics

Innovative Ketamine Formulations: Enhancing Therapeutic Efficacy and Safety.

ACS Medicinal Chemistry Letters August 8, 2024 Robert B. Kargbo 1 citation

Ketamine, originally developed as an anesthetic, has shown significant potential for treating depression, chronic pain, and other conditions. However, its conventional formulations often result in side effects such as hallucinations and dizziness due to rapid spikes in blood concentration. This article explores recent patents that optimize ketamine delivery and efficacy: subcutaneous injectable...

DOI: 10.1021/acsmedchemlett.4c00330 Full text Ketamine-therapy Drug-delivery-systems Pharmaceutical-innovation Depression-treatment

Papers